Weight Management

Glucagon-like peptide-1 agonists have increasingly showed potential for treating liver fibrosis in patients, which disproportionately affects those who are overweight or have obesity.

Off-label semaglutide has been linked to serious adverse effects, calling for increased regulation around compounding.

In addition to GLP-1s, dual GLP-1 and GIP agonists, intestinal lipase inhibitors, sympathomimetics, and other agents can help patients lose weight.

Glucagon-like peptide-1 (GLP-1) receptor agonists are widely known as treatments for type 2 diabetes, though some have been approved for indications beyond diabetes.

The call follows the FDA’s sudden removal of tirzepatide from the drug shortage list, preventing compounding pharmacies from providing the drug.

The agency does not intend to take action against the plaintiffs for the violation of the Federal Food, Drug, and Cosmetic Act, including the compounding of tirzepatide.

Pharmacists can educate patients about how to recognize unsafe online sources of medications and ensure patients are properly educate on how to administer their medications.

Questions in the pharmacy are endless and often hard to answer.

The lawsuit alleges that the action was taken without the required notice and disputes the agency’s warning of “localized supply disruption,” while calling for more transparency.

In previous studies, semaglutide was found to modulate dopamine reward signaling and decreased drug rewards (specifically heroin) in rodents.

Treatment with tirzepatide has led not only to significant reductions in excess body weight, but also improvements in blood pressure and reduction of inflammatory markers.

As of now, data suggest minimal risk of drug interactions between oral contraceptives and injectable semaglutide.

Surprisingly, those with overweight BMI at diagnosis did not have a poor prognosis.

For adults receiving the 15 mg dose, tirzepatide sustained weight loss with an average reduction of 22.9% in body weight compared with 2.1% for the placebo.

Glucagon-like peptide-1 receptor agonists and sodium-glucose contransporter-2 inhibitors have been added as first-line therapy recommendation for type 2 diabetes, the first since metformin

Pharmacists play an important role in managing patients with this complex condition.

The system is an outpatient procedure that resurfaces the mucosal lining, making it easier for the body to maintain healthy metabolism and blood glucose levels.

A 5:2 intermittent fasting plan combined with meal replacement had better positive outcomes compared with metformin and empagliflozin.

Anatomical alterations result in many downstream changes, such as changes in pH, gastric volume, food intake, surface area for absorption, gastric emptying and transit times, and intestinal enzymes and efflux pumps, among others.

Use of semaglutide injections may be linked to an increased risk of blindness in patients with diabetes.

The FDA has issued a statement on suicidal thoughts or actions and has launched evaluations for that signal as well as alopecia and aspiration.

Based on these results, tirzepatide could be first medication approved for treatment of obstructive sleep apnea in patients with obesity.

Ensuring broad access to weight management solutions is vital for addressing entrenched health inequities, improving health outcomes, and reducing individual and societal health costs.

Research has found that increased consumption of sugar alcohols, like xylitol, may increase risk of cardiovascular events.

Providers, the community, health systems, and health policies can all play a part in addressing various challenges in care for obesity.

Added data from the SELECT trial helps to increase confidence in safety and efficacy of semaglutide, a glucagon-like peptide 1 medication.

The GLP-1 market is expected to exceed $100 billion by 2023, according to J.P. Morgan Research, with total users in the United States projected to reach 30 million.

The oral medication activates an “anti-hunger” molecule which may prevent people from overeating.

According to the results, approximately 82% of adults said they have heard at least a little about GLP-1 medications and 32% said they have heard a lot.

Novo Nordisk and Eli Lilly have spoken out against the use of their GLP-1 medications for cosmetic weight loss, emphasizing the proper use of their medications.